局部晚期可手术食管癌经新辅助放化疗达临床完全缓解后的处理策略

doi:10.3760/cma.j.cn371439-20230828-00140

国际肿瘤学杂志 ›› 2023, Vol. 50 ›› Issue (12): 745-750.doi: 10.3760/cma.j.cn371439-20230828-00140

局部晚期可手术食管癌经新辅助放化疗达临床完全缓解后的处理策略

巩合义¹, 伊艳²^,³, 张健¹, 李宝生²()

¹山东第一医科大学附属中心医院肿瘤科，济南 250013
²山东省肿瘤防治研究院山东第一医科大学附属肿瘤医院放疗科山东省放射肿瘤学重点实验室，济南 250117
³天津医科大学肿瘤医院国家肿瘤临床医学研究中心天津市肿瘤防治重点实验室天津市恶性肿瘤临床医学研究中心，天津 300060

收稿日期:2023-08-28 修回日期:2023-09-19 出版日期:2023-12-08 发布日期:2024-01-16
通讯作者: 李宝生 E-mail:baoshli1963@163.com
基金资助:
山东省自然科学基金(ZR2022ZD31)

Management strategies for locally advanced operable esophageal carcinoma achieving clinical complete response after neoadjuvant chemoradiotherapy

Gong Heyi¹, Yi Yan²^,³, Zhang Jian¹, Li Baosheng²()

¹Department of Oncology， Affiliated Central Hospital of Shandong First Medical University， Jinan 250013， China
²Department of Radiation Oncology， Shandong Cancer Hospital and Institute Affiliated to Shandong First Medical University， Shandong Provincial Key Laboratory of Radiation Oncology， Jinan 250117， China
³Cancer Hospital of Tianjin Medical University， National Clinical Research Center for Cancer， Tianjin Key Laboratory of Cancer Prevention and Treatment， Tianjin Clinical Research Center for Cancer， Tianjin 300060， China

Received:2023-08-28 Revised:2023-09-19 Online:2023-12-08 Published:2024-01-16
Contact: Li Baosheng E-mail:baoshli1963@163.com
Supported by:
Natural Science Foundation of Shandong Province of China(ZR2022ZD31)

摘要/Abstract

摘要：

局部晚期可手术食管癌的标准治疗模式是新辅助放化疗+根治性食管切除术，但鉴于器官保留的临床需求，经新辅助放化疗达临床完全缓解后的处理策略包括等待观察（免手术）、延迟性或挽救性手术、加强系统治疗等，这些处理策略在保证患者局部控制和长期生存的基础上，可显著改善其生命质量。深入探讨这些处理策略的可行性、临床价值，期望为这部分患者提供新的治疗思路。

关键词: 食管肿瘤, 放化疗，辅助, 等待观察, 挽救性手术, 系统治疗

Abstract:

The standard treatment mode for locally advanced operable esophageal carcinoma is neoadjuvant chemoradiotherapy combined with radical esophagectomy. However， considering the clinical need for organ retention， the treatment strategies for those achieving complete clinical response after neoadjuvant chemoradiotherapy include watchful waiting （omitting surgery）， delayed or salvage surgery， and strengthened systemic treatment. These treatment strategies can significantly improve the quality of patients' life while ensuring local control and long-term survival. The feasibility and clinical value of these treatment strategies are deeply explored， hoping to provide new treatment ideas for this group of patients.

Key words: Esophageal neoplasms, Chemoradiotherapy， adjuvant, Wait and see, Salvage surgery, Systemic therapy

巩合义, 伊艳, 张健, 李宝生. 局部晚期可手术食管癌经新辅助放化疗达临床完全缓解后的处理策略[J]. 国际肿瘤学杂志, 2023, 50(12): 745-750.

Gong Heyi, Yi Yan, Zhang Jian, Li Baosheng. Management strategies for locally advanced operable esophageal carcinoma achieving clinical complete response after neoadjuvant chemoradiotherapy[J]. Journal of International Oncology, 2023, 50(12): 745-750.

参考文献 30

[1]	Yang Y, Liu Z, Sun Y, et al. Clinical characteristics and survival of esophageal cancer patients: annual report of the surgical treatment in Shanghai Chest Hospital, 2016[J]. J Thorac Dis, 2022, 14(12): 4966-4982. DOI: 10.21037/jtd-22-1672. pmid: 36647485
[2]	Khaitan PG, Holliday T, Carroll A, et al. Can clinical response predict pathologic response following neoadjuvant chemoradiation for esophageal cancer?[J]. J Gastrointest Surg, 2022, 26(7): 1345-1351. DOI: 10.1007/s11605-022-05315-y. pmid: 35414141
[3]	Noordman BJ, Spaander MCW, Valkema R, et al. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study[J]. Lancet Oncol, 2018, 19(7): 965-974. DOI: 10.1016/S1470-2045(18)30201-8. pmid: 29861116
[4]	Eyck BM, van der Wilk BJ, Noordman BJ, et al. Updated protocol of the SANO trial: a stepped-wedge cluster randomised trial comparing surgery with active surveillance after neoadjuvant chemoradiotherapy for oesophageal cancer[J]. Trials, 2021, 22(1): 345. DOI: 10.1186/s13063-021-05274-w. pmid: 34001287
[5]	van der Wilk BJ, Noordman BJ, Neijenhuis LKA, et al. Active surveillance versus immediate surgery in clinically complete responders after neoadjuvant chemoradiotherapy for esophageal cancer: a multicenter propensity matched study[J]. Ann Surg, 2021, 274(6): 1009-1016. DOI: 10.1097/SLA.0000000000003636.
[6]	Zhang X, Eyck BM, Yang Y, et al. Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study[J]. BMC Cancer, 2020, 20(1): 194. DOI: 10.1186/s12885-020-6669-y. pmid: 32143580
[7]	van der Zijden CJ, Lagarde SM, Hermus M, et al. A prospective cohort study on active surveillance after neoadjuvant chemoradiotherapy for esophageal cancer: protocol of surgery as needed for oesophageal cancer-2[J]. BMC Cancer, 2023, 23(1): 327. DOI: 10.1186/s12885-023-10747-z. pmid: 37038138
[8]	Bedenne L, Mariette C. Comparison of systematic surgery versus surveillance and rescue surgery in operable oesophageal cancer with a complete clinical response to radiochemotherapy (esostrate)[DB/OL]. [2019-12-20]. https://clinicaltrials.gov/ct2/show/NCT02551458.
[9]	中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)食管癌诊疗指南2023[EB/OL].[2023-10-16]. https://meeting.csco.org.cn/pdf/web/viewer.html?file=/Upload/Periodical/20231016021009.pdf.
[10]	Yu J, Kim JH, Kim SB, et al. Role of esophagectomy after chemoradiation therapy in patients with locally advanced squamous cell carcinoma: a comparative analysis stratified by clinical response to chemoradiation therapy[J]. Cancer Res Treat, 2022, 54(4): 1148-1156. DOI: 10.4143/crt.2021.885.
[11]	Park J, Yea JW, Oh SA, et al. Omitting surgery in esophageal cancer patients with complete response after neoadjuvant chemoradiotherapy: a systematic review and meta-analysis[J]. Radiat Oncol, 2021, 16(1): 219. DOI: 10.1186/s13014-021-01947-7. pmid: 34775988
[12]	van der Wilk BJ, Eyck BM, Hofstetter WL, et al. Chemoradiotherapy followed by active surveillance versus standard esophagectomy for esophageal cancer: a systematic review and individual patient data meta-analysis[J]. Ann Surg, 2022, 275(3): 467-476. DOI: 10.1097/SLA.0000000000004930.
[13]	Vellayappan BA, Soon YY, Ku GY, et al. Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer[J]. Cochrane Database Syst Rev, 2017, 8(8): CD010511. DOI: 10.1002/14651858.CD010511.pub2.
[14]	Wang J, Qin J, Jing S, et al. Clinical complete response after chemoradiotherapy for carcinoma of thoracic esophagus: is esophagectomy always necessary? A systematic review and meta-analysis[J]. Thorac Cancer, 2018, 9(12): 1638-1647. DOI: 10.1111/1759-7714.12874. pmid: 30277016
[15]	Goense L, Ruurda JP, Carter BW, et al. Prediction and diagnosis of interval metastasis after neoadjuvant chemoradiotherapy for oesophageal cancer using ¹⁸F-FDG PET/CT[J]. Eur J Nucl Med Mol Imaging, 2018, 45(10): 1742-1751. DOI: 10.1007/s00259-018-4011-6.
[16]	Faiz Z, Kats-Ugurlu G, Mui VEM, et al. Locoregional residual esophageal cancer after neo-adjuvant chemoradiotherapy and surgery regarding anatomic site and radiation target fields: a histopathologic evaluation study[J]. Ann Surg, 2022, 275(6): e759-e765. DOI: 10.1097/SLA.0000000000004242.
[17]	Levinsky NC, Wima K, Morris MC, et al. Outcome of delayed versus timely esophagectomy after chemoradiation for esophageal adenocarcinoma[J]. J Thorac Cardiovasc Surg, 2020, 159(6): 2555-2566. DOI: 10.1016/j.jtcvs.2019.09.169. pmid: 31767364
[18]	Faiz Z, Dijksterhuis WPM, Burgerhof JGM, et al. A meta-analysis on salvage surgery as a potentially curative procedure in patients with isolated local recurrent or persistent esophageal cancer after chemoradiotherapy[J]. Eur J Surg Oncol, 2019, 45(6): 931-940. DOI: 10.1016/j.ejso.2018.11.002. pmid: 30447937
[19]	Park SR, Yoon DH, Kim JH, et al. A randomized phase Ⅲ trial on the role of esophagectomy in complete responders to preoperative chemoradiotherapy for esophageal squamous cell carcinoma (ESOPRESSO)[J]. Anticancer Res, 2019, 39(9): 5123-5133. DOI: 10.21873/anticanres.13707.
[20]	Sugawara K, Yagi K, Okumura Y, et al. Long-term outcomes of multimodal therapy combining definitive chemoradiotherapy and salvage surgery for T₄ esophageal squamous cell carcinoma[J]. Int J Clin Oncol, 2020, 25(4): 552-560. DOI: 10.1007/s10147-019-01590-z. pmid: 31828451
[21]	Swisher SG, Moughan J, Komaki RU, et al. Final results of NRG oncology RTOG 0246: an organ-preserving selective resection strategy in esophageal cancer patients treated with definitive chemoradiation[J]. J Thorac Oncol, 2017, 12(2): 368-374. DOI: 10.1016/j.jtho.2016.10.002.
[22]	郭旭峰, 孙益峰, 杨煜, 等. 食管癌根治性放化疗后挽救性手术: 单一手术组18例临床分析[J]. 中华胸心血管外科杂志, 2018, 34(2): 76-78. DOI: 10.3760/cma.j.issn.1001-4497.2018.02.003.
[23]	Eyck BM, Hulshof MCCM, et al. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial[J]. J Clin Oncol, 2021, 39(18): 1995-2004. DOI: 10.1200/JCO.20.03614.
[24]	Liu S, Wen J, Yang H, et al. Recurrence patterns after neoadjuvant chemoradiotherapy compared with surgery alone in oesophageal squamous cell carcinoma: results from the multicenter phase Ⅲ trial NEOCRTEC5010[J]. Eur J Cancer, 2020, 138: 113-121. DOI: 10.1016/j.ejca.2020.08.002.
[25]	Barbetta A, Sihag S, Nobel T, et al. Patterns and risk of recurrence in patients with esophageal cancer with a pathologic complete response after chemoradiotherapy followed by surgery[J]. J Thorac Cardiovasc Surg, 2019, 157(3): 1249-1259.e5. DOI: 10.1016/j.jtcvs.2018.09.136. pmid: 30655068
[26]	Kermani AT, Bagheri R, Taheri H, et al. Evaluation of survival and recurrence patterns in esophageal cancer patients with pathological response to neoadjuvant chemoradiotherapy[J]. Kardiochir Torakochirurgia Pol, 2019, 16(4): 186-193. DOI: 10.5114/kitp.2019.91388.
[27]	Wang X, Yu N, Cheng G, et al. Prognostic value of circulating tumour DNA during post-radiotherapy surveillance in locally advanced esophageal squamous cell carcinoma[J]. Clin Transl Med, 2022, 12(11): e1116. DOI: 10.1002/ctm2.1116. pmid: 36437506
[28]	Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer[J]. N Engl J Med, 2021, 384(13): 1191-1203. DOI: 10.1056/NEJMoa2032125.
[29]	Park S, Sun JM, Choi YL, et al. Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase Ⅱ study[J]. ESMO Open, 2022, 7(1): 100385. DOI: 10.1016/j.esmoop.2022.100385.
[30]	Schizas D, Mylonas KS, Kapsampelis P, et al. Patients under-going surgery for oligometastatic oesophageal cancer survive for more than 2 years: bootstrapping systematic review data[J]. Interact Cardiovasc Thorac Surg, 2020, 31(3): 299-304. DOI: 10.1093/icvts/ivaa116.

局部晚期可手术食管癌经新辅助放化疗达临床完全缓解后的处理策略

Management strategies for locally advanced operable esophageal carcinoma achieving clinical complete response after neoadjuvant chemoradiotherapy

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 30

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[2]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[3]	万芳, 杨钢, 李睿, 万启晶. 食管癌患者血清miR-497、miR-383水平及临床意义[J]. 国际肿瘤学杂志, 2024, 51(4): 204-209.
[4]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 中国食管癌放射治疗指南（2023年版）[J]. 国际肿瘤学杂志, 2024, 51(1): 1-20.
[5]	高新雨, 李振江, 孙洪福, 韩丹, 赵倩, 刘成新, 黄伟. 基于MR加速器的MR引导放疗在食管癌患者中的临床应用[J]. 国际肿瘤学杂志, 2024, 51(1): 37-42.
[6]	山东省医学会肺癌食管癌多学科联合委员会. 山东省医学会食管癌多学科规范化诊疗指南（2023年版）[J]. 国际肿瘤学杂志, 2023, 50(7): 385-397.
[7]	冀世玉, 张明鑫, 谢华红, 白渊, 王彤. 不同支架治疗晚期食管癌患者的疗效观察[J]. 国际肿瘤学杂志, 2023, 50(2): 76-81.
[8]	吴浦嫄, 祁亮, 王涛, 史敏科, 孙雨薇, 王立峰, 刘宝瑞, 闫婧, 任伟. 基于高频复发区改良临床靶区的术后放疗在食管鳞状细胞癌中的疗效研究[J]. 国际肿瘤学杂志, 2022, 49(8): 464-472.
[9]	戴李宸, 胡莉钧, 于静萍. 尼妥珠单抗治疗食管鳞状细胞癌的应用进展[J]. 国际肿瘤学杂志, 2022, 49(8): 484-489.
[10]	夏玲玲, 陈永顺, 李彬, 宁婷婷, 张蔡羽天. pN₊食管鳞状细胞癌患者R0切除术后放化疗与化疗的安全性及有效性比较[J]. 国际肿瘤学杂志, 2022, 49(6): 334-339.
[11]	叶倩, 凌志, 刘申香, 路国涛, 殷旭东. 肌肉减少症对老年食管癌患者根治性放疗临床疗效及预后的影响[J]. 国际肿瘤学杂志, 2022, 49(4): 199-205.
[12]	周剑烽, 王铁君. 食管癌的靶向治疗及免疫治疗[J]. 国际肿瘤学杂志, 2022, 49(4): 237-242.
[13]	刘佳, 葛小林, 狄晓珂, 史玉静, 曾玉婷. 喜炎平注射液预防放射性食管炎的疗效分析[J]. 国际肿瘤学杂志, 2022, 49(3): 146-150.
[14]	张俊鹏, 于燕燕, 李宝生. lncRNA、circRNA调控食管鳞状细胞癌放化疗敏感性的作用机制[J]. 国际肿瘤学杂志, 2022, 49(3): 185-189.
[15]	耿惠, 胡锋超, 路洪超, 郭军岗, 齐增平. TPF方案同步IMRT治疗对中晚期食管癌患者免疫功能及生存预后的影响[J]. 国际肿瘤学杂志, 2022, 49(2): 84-88.